Abigail R. Edwards

This paper shows that IL-1-activated cancer-associated fibroblasts (iCAFs) promote STAT1-driven transcriptional reprogramming in pancreatic tumour cells, leading to chemoresistance and identifying STAT1 as a therapeutic target.

This study shows that inhibiting Myc in pancreatic tumours triggers GM-CSF release, which drives tumour regression via cDC1s, offering a new therapeutic strategy for PDAC.

The paper assesses neoadjuvant axitinib response in RCC with VTT using multiparametric analysis and identifies angiogenic and immune predictors of treatment response.